169 
Fig 1. Visual representation of cytokine reduction levels.
✏️ ADMIN EDIT MODE
local_hospital
MedJournal
Research chevron_right Immunology
Targeted Immunotherapy in Chronic Autoimmune Disorders
A comprehensive analysis of novel monoclonal antibody treatments and their long-term efficacy in Phase III clinical trials.
Dr. Sarah Chen, MD, PhD
Lead Researcher, Stanford Medicine
summarize Abstract
This study evaluates the efficacy of specific monoclonal antibodies in reducing inflammation markers in patients with rheumatoid arthritis.
Introduction
Autoimmune diseases affect approximately 5% of the population. Current treatments often rely on broad immunosuppression.
Figure 1: Patient Response Rates
Results
- Efficacy: 78% of patients achieved remission.
- Safety: Adverse events were comparable to placebo.
Cite This Article
Chen, S. (2025). Targeted Immunotherapy. MedJournal, 12(4).
